Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval
- Enrolment completed – 120 patients with end-stage renal disease in 22 centers in Europe
- Primary endpoint readouts anticipated in Q2 2025, first market approval expected in 2026
- Capability to obtain market approval is further strengthened with the appointment of Rob Eyers as Chief Technology Officer.
EINDHOVEN, The Netherlands, 7 January 2025 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces the completion of enrolment in its EU Pivotal trial for aXess, its restorative vascular access conduit, in adults with end-stage renal disease. The trial is taking place in 22 centers across Europe.
